# ADRIATIC (NCT03703297)

> Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03703297
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Small Cell Lung Cancer
- Interventions: Durvalumab; Tremelimumab; Placebo
- Enrollment: 730
- Primary outcome: Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1
- Primary outcome: Durvalumab Versus Placebo: Overall Survival (OS)

## Commentary we found

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=adriatic-nct03703297